Om3gafort^SCC DHA Premium – Spain

Daily dietary supplement containing HIGH CONCENTRATION omega-3:

Om3gafort^SCC uses HIGH CONCENTRATION Omega-3 polyunsaturated fatty acids EPA/DHA, EFFICACY, PURITY and SAFETY obtained with an ENVIRONMENTALLY FRIENDLY technology known as Supercritical Concentration (SCC).

Om3gafort^SCC DHA^SCC uses LiqFillCaps^TM hard capsules that facilitate better absorption of DHA in the body.

LiqFillCaps^TM are an innovative technological concept that provide effective solutions for many of the challenges faced by the pharmaceutical and neutraceutical industry. In particular those related to the low solubility of bioactive ingredients and agents, thus obtaining increased oral bioavailability and absorption.

SUPPLEMENT FACTS

NUTRITION FACTS

Daily dose: 2 capsules. % DV based on daily dose.

*Recommended daily amount as per Directive 2008/100/CE of 28 October 2008.
**Daily value not established.
#Guaranteed minimum quantity of the active ingredient expressed in mg. Percentages calculated on the basis of the minimum quantity expressed in mg are subject to variation.

INGREDIENTS:

Fish Oil: (minimum 55% DHA, minimum 5% EPA), Gelatin, Emulsifier: Soya lecithin, Antioxidants: natural mixed tocopherols, Color Additives (E132).

Greater concentration, greater efficacy

Children and adolescents:

1. McNamara RK, Able J, Jandacek R, Rider T, Tso P, Eliassen JC, Alfieri D, Weber W, Jarvis K, DelBello MP, Strakowski SM, Adler CM. Docosahexaenoic acid supplementation increases prefrontal cortex activation during sustained attention in healthy boys: a placebo-controlled, dose-ranging, functional magnetic resonance imaging study. Am J Clin Nutr. 2010 Apr;91(4):1060-7.
2. Ryan AS, Astwood JD, Gautier S, Kuratko CN, Nelson EB, Salem N Jr. Effects of long-chain polyunsaturated fatty acid supplementation on neurodevelopment in childhood: a review of human studies. Prostaglandins Leukot Essent Fatty Acids. 2010 Apr-Jun;82(4-6):305-14. Epub 2010 Feb 25.
3. Bazan NG. Cellular and molecular events mediated by docosahexaenoic acid-derived neuroprotectin D1 signaling in photoreceptor cell survival and brain protection. Prostaglandins Leukot Essent Fatty Acids. 2009 Aug-Sep;81(2-3):205-11. Epub 2009 Jun 11.
4. Lien VW, Clandinin MT. Dietary assessment of arachidonic acid and docosahexaenoic acid intake in 4-7 year-old children. J Am Coll Nutr. 2009 Feb;28(1):7-15.
5. Innis SM. Omega-3 Fatty acids and neural development to 2 years of age: do we know enough for dietary recommendations? J Pediatr Gastroenterol Nutr. 2009 Mar;48 Suppl 1:S16-24.
6. Makrides M. Is there a dietary requirement for DHA in pregnancy? Prostaglandins Leukot Essent Fatty Acids. 2009 Aug-Sep;81(2-3):171-4. Epub 2009 Jun 4.
7. Koletzko B, Beblo S, Demmelmair H, Müller-Felber W, Hanebutt FL. Does dietary DHA improve neural function in children? Observations in phenylketonuria. Prostaglandins Leukot Essent Fatty Acids. 2009 Aug-Sep;81(2-3):159-64. Epub 2009 Jul 16.
8. Cheatham CL, Colombo J, Carlson SE. N-3 fatty acids and cognitive and visual acuity development: methodologic and conceptual considerations. Am J Clin Nutr. 2006 Jun;83(6 Suppl):1458S-1466S.
9. Fleith M, Clandinin MT. Dietary PUFA for preterm and term infants: review of clinical studies. Crit Rev Food Sci Nutr. 2005;45(3):205-29.
10. Auestad N, Scott DT, Janowsky JS, Jacobsen C, Carroll RE, Montalto MB, Halter R, Qiu W, Jacobs JR, Connor WE, Connor SL, Taylor JA, Neuringer M, Fitzgerald KM, Hall RT. Visual, cognitive, and language assessments at 39 months: a follow-up study of children fed formulas containing long-chain polyunsaturated fatty acids to 1 year of age. Pediatrics. 2003 Sep;112(3 Pt 1):e177-83.

ADHD

1. Schuchardt JP, Huss M, Stauss-Grabo M, Hahn A. Significance of long-chain polyunsaturated fatty acids (PUFAs) for the development and behaviour of children. Eur J Pediatr. 2010 Feb;169(2):149-64. Epub 2009 Aug 12.
2. Bélanger SA, Vanasse M, Spahis S, Sylvestre MP, Lippé S, L’heureux F, Ghadirian P, Vanasse CM, Levy E. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: A randomized, double-blind, placebo-controlled study. Paediatr Child Health. 2009 Feb;14(2):89-98.
3. Vaisman N, Kaysar N, Zaruk-Adasha Y, Pelled D, Brichon G, Zwingelstein G, Bodennec J. Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: effect of dietary n-3 fatty acids containing phospholipids. Am J Clin Nutr. 2008 May;87(5):1170-80.
4. Frölich J, Döpfner M. The treatment of Attention-Deficit/Hyperactivity Disorders with polyunsaturated fatty acids – an effective treatment alternative? Z Kinder Jugendpsychiatr Psychother. 2008 Mar;36(2):109-16.
5. Sorgi PJ, Hallowell EM, Hutchins HL, Sears B. Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder. Nutr J. 2007 Jul 13;6:16.
6. Stevens L, Zhang W, Peck L, Kuczek T, Grevstad N, Mahon A, Zentall SS, Arnold LE, Burgess JR. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids. 2003 Oct;38(10):1007-21.

Adults:

1. Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS, Blackwell A, Salem N Jr, Stedman M; on behalf of the MIDAS Investigators. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement. 2010 Apr 29
2. Muldoon MF, Ryan CM, Sheu L, Yao JK, Conklin SM, Manuck SB. Serum phospholipid docosahexaenonic acid is associated with cognitive functioning during middle adulthood. J Nutr. 2010 Apr;140(4):848-53. Epub 2010 Feb 24.
3. Robinson JG, Ijioma N, Harris W. Omega-3 fatty acids and cognitive function in women. Womens Health (Lond Engl). 2010 Jan;6(1):119-34.
4. McNamara RK. Evaluation of docosahexaenoic acid deficiency as a preventable risk factor for recurrent affective disorders: current status, future directions, and dietary recommendations. Prostaglandins Leukot Essent Fatty Acids. 2009 Aug-Sep;81(2-3):223-31. Epub 2009 Jun 9.

Seniors:

1. Lukiw WJ, Bazan NG. Docosahexaenoic acid and the aging brain. J Nutr. 2008 Dec;138(12):2510-4.
2. Freemantle E, Vandal M, Tremblay-Mercier J, Tremblay S, Blachère JC, Bégin ME, Brenna JT, Windust A, Cunnane SC. Omega-3 fatty acids, energy substrates, and brain function during aging. Prostaglandins Leukot Essent Fatty Acids. 2006 Sep;75(3):213-20.

LiqFillCaps^TM are an innovative technological concept that provides an efficient solution to the many challenges the pharmaceutical and nutraceutical industries face, in particular those due to the low solubility of active ingredients and bioactive agents, thereby helping to achieve an increase in both oral bioavailability and absorption.